🟢 Painreform is trading 6.18% up in pre-market with no clear company-specific catalyst

Painreform is trading 6.18% up in pre-market at $1.01, with no clear company-specific catalyst identified for September 2, 2026.

• The latest identifiable announcement, published June 25, reported expanded preclinical PRF-110 results with comparable analgesic efficacy to ZYNRELEF; it was not a new overnight event.
• Broader markets are mixed, with major indexes near flat, so global sentiment does not clearly explain the gain.
• The move may reflect low-liquidity pre-market activity.